Achieve Life Sciences (ACHV) Short term Debt (2016 - 2025)

Achieve Life Sciences (ACHV) posted Short term Debt of $1.6 million for Q4 2025, up 7.9% on a QoQ basis from $1.4 million in Q3 2025.

Achieve Life Sciences (ACHV) Short term Debt (2016 - 2025) Analysis & Trends

Achieve Life Sciences' Short term Debt history runs 6 years deep, the most recent figure standing at $1.6 million for Q4 2025.

Quarterly Short term Debt changed N/A year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (changed N/A YoY) and the FY2025 annual result came in at $1.6 million, changed N/A from the prior year.
Short term Debt was $1.6 million for Q4 2025 at Achieve Life Sciences, up from $1.4 million in the prior quarter.
Across five years, Short term Debt topped out at $17.1 million in Q1 2024 and bottomed at $528000.0 in Q4 2023.
A 4-year average of $7.1 million and a median of $1.6 million in 2025 frame the typical range for Short term Debt.
Annual changes were most pronounced in 2023 — Short term Debt sank 96.71% — and 2024, when it gained 4.7%.
Achieve Life Sciences' Short term Debt stood at $16.1 million in 2022, then sank by 96.71% to $528000.0 in 2023, then jumped by 1567.42% to $8.8 million in 2024, then plunged by 82.31% to $1.6 million in 2025.
Business Quant data shows ACHV's Short term Debt at $1.6 million in Q4 2025, $1.4 million in Q3 2025, and $1.2 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Achieve Life Sciences	2.54 Mn	2.54 Mn	-

Download Data